Latest Temozolomide Stories
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma
VAL-083 Anti-tumor Activity Is Consistently Superior to Temozolomide in Preclinical Models of Glioblastoma VANCOUVER, British Columbia, MENLO PARK, Calif., and MIAMI, Nov.
Continued Positive Trends in Overall Survival and Progression-Free Survival; LOS ANGELES, Nov. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Interim analysis of the pivotal phase III trial of Tumor Treating Fields in newly diagnosed glioblastoma (EF-14) will be presented as a late-breaking oral presentation ST.
HEIDELBERG, Germany, Oct.
DelMar Is Advancing Clinical Trials With VAL-083 As A New Chemotherapy For Refractory Glioblastoma Multiforme VANCOUVER, British Columbia and MENLO PARK, Calif., Aug.
VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug.
VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB:
In this phase two study, 50 percent of glioblastoma patients lived for two years, an encouraging result for one of the most deadly cancers that often kills patients within one year of diagnosis
- totally perplexed and mixed up.